Does Fallon Community Health Plan (FCHP) Cover Forteo?

What Is Forteo and Why Does It Require Special Coverage Review?

Teriparatide, sold as Forteo by Eli Lilly, is a recombinant fragment of human parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than simply slowing bone loss. The FDA approved teriparatide in November 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis [1]. Because it is injected daily via a prefilled pen, requires refrigeration, and carries a cumulative lifetime limit of 24 months, payers including FCHP classify it as a high-cost specialty medication subject to medical necessity review before dispensing.

The key fracture-reduction trial, a randomized controlled study published in the New England Journal of Medicine (N=1,637), showed that teriparatide 20 mcg/day reduced new vertebral fractures by 65% and non-vertebral fragility fractures by 53% relative to placebo over a median of 21 months [2]. That efficacy is substantial, but the annual drug cost exceeds $30,000 per patient at list price, which explains why FCHP and essentially every major U.S. health plan tier the drug at the specialty level and require documentation before approving it [3].

The FDA's prescribing information carries a boxed warning about osteosarcoma risk observed in rat studies at supraphysiologic doses; the FDA removed this warning in January 2021 after post-marketing surveillance showed no signal in humans over nearly two decades of use [1]. Clinicians should document this updated safety profile in prior authorization letters, because older FCHP denial templates sometimes still reference the boxed warning as a rationale for restriction.

How FCHP Structures Its Pharmacy Benefit for Specialty Drugs

FCHP operates multiple product lines, including commercial HMO and PPO plans, Medicare Advantage plans (branded as Fallon Senior Plan), and MassHealth Accountable Care plans for Medicaid-eligible Massachusetts residents. Each product line uses a distinct formulary, so the specific tier, copay, and step-therapy requirements for Forteo differ across these populations [4].

On commercial plans, specialty drugs are typically subject to a 20-30% coinsurance after the deductible, with specialty tier drugs dispensed through a designated specialty pharmacy rather than a retail chain. FCHP has historically contracted with specialty pharmacies that handle temperature-sensitive injectables, which Forteo requires given its 36-46°F storage requirement [1].

On Medicare Advantage plans, teriparatide falls under Part D pharmacy benefit rules. CMS data from 2024 show that the median Part D specialty tier cost-sharing for biologics is $106 per 30-day supply after the deductible phase, though the Inflation Reduction Act's $2,000 out-of-pocket cap for Part D enrollees beginning in 2025 changes the calculus significantly for high-cost drugs like Forteo [5]. The Medicare Part D Low-Income Subsidy (LIS) can reduce teriparatide cost-sharing to as low as $11.20 for full-subsidy beneficiaries in 2025 [5].

MassHealth Accountable Care members face a different structure. MassHealth covers teriparatide as a carve-out specialty drug with a $3.65 copay maximum for eligible members, though prior authorization is still required [4].

Prior Authorization Criteria FCHP Typically Applies to Forteo

FCHP's prior authorization criteria for teriparatide align closely with American Association of Clinical Endocrinology (AACE) 2020 guidelines, which stratify patients into moderate, high, and very-high fracture risk categories and recommend anabolic therapy for the very-high-risk group as initial treatment rather than as a last resort [6]. Despite that clinical recommendation, most FCHP commercial formularies still require bisphosphonate step therapy first, reflecting a cost-management policy that the AACE guidelines themselves explicitly caution against for very-high-risk patients [6].

Typical FCHP prior authorization requirements for Forteo include all of the following:

Diagnosis documentation. A DXA scan result showing a T-score of -2.5 or below at the lumbar spine, total hip, or femoral neck, or a documented fragility fracture, or both. The Endocrine Society's 2019 clinical practice guideline defines osteoporosis as a T-score at or below -2.5 or a fragility fracture at any T-score [7].

Step therapy. At least 12 months of treatment with an oral bisphosphonate (alendronate, risedronate, or ibandronate) or intravenous zoledronic acid (Reclast, 5 mg annually), with documented failure defined as either continued bone loss on DXA or an incident fracture while on therapy, or a documented contraindication or intolerance such as esophageal disease, severe renal impairment (CrCl <35 mL/min for oral agents), or severe GI intolerance [8].

Prescriber qualification. FCHP often requires that the prescribing clinician be an endocrinologist, rheumatologist, or other specialist with documented expertise in metabolic bone disease, though primary care providers who submit thorough documentation are generally approved as well.

Quantity limits. One 28-dose pen (600 mcg/2.4 mL) per 28-day supply, consistent with the FDA-approved 20 mcg daily dose [1].

Duration of therapy. Initial approval typically covers 6 months. Continuation requires a re-authorization documenting adherence, absence of new contraindications, and that the cumulative 24-month lifetime limit has not been reached [1].

Step Therapy: The Bisphosphonate Requirement in Clinical Context

The step-therapy requirement to trial bisphosphonates before teriparatide approval is the most common reason for initial denial in FCHP plans. Bisphosphonates remain first-line therapy for most patients based on their fracture-reduction data, low cost, and oral availability. Alendronate 70 mg weekly reduced vertebral fracture risk by 47% and hip fracture risk by 51% in the Fracture Intervention Trial (N=2,027) [8]. Zoledronic acid 5 mg annually reduced vertebral fractures by 70% and hip fractures by 41% in the HORIZON Key Fracture Trial (N=7,765) [9].

Short. But those numbers matter only if the patient can take bisphosphonates safely and tolerates them adequately.

For patients with a T-score below -3.5, a history of hip or vertebral fracture, or multiple prior fractures, the AACE 2020 guidelines state explicitly: "Anabolic therapy should be considered as first-line treatment for very-high-risk patients and should not be delayed pending bisphosphonate trials." [6] A member's physician can use this language verbatim in a prior authorization letter to FCHP to argue for a step-therapy exception.

Massachusetts law provides additional protection. Under M.G.L. c. 176O, section 13, health plans operating in Massachusetts, including FCHP, must grant a step-therapy exception within 72 hours (or 24 hours for urgent requests) if a clinician documents that the required step-therapy drug is contraindicated, has been previously tried and failed, or is not clinically appropriate for that specific patient [4]. This statutory exception pathway is the fastest route when a very-high-risk patient needs teriparatide immediately after a fragility fracture.

Formulary Alternatives FCHP May Prefer Over Forteo

FCHP formularies list several agents in the same anabolic or high-potency anti-resorptive category that may be placed on lower tiers or face fewer restrictions than teriparatide.

Abaloparatide (Tymlos). A PTH-related protein analog approved by the FDA in April 2017, abaloparatide 80 mcg daily demonstrated a 43% reduction in new vertebral fractures versus placebo in the ACTIVE trial (N=2,463) [10]. Radius Health's list price is slightly below Forteo's, and some FCHP formularies place Tymlos at a more accessible tier, making it a potential alternative if the prescriber is open to it.

Romosozumab (Evenity). A sclerostin inhibitor approved in April 2019, romosozumab 210 mg monthly by subcutaneous injection for 12 months showed a 73% reduction in new vertebral fractures versus placebo in the FRAME trial (N=7,180) [11]. FCHP Medicare Advantage plans may handle romosozumab under the medical benefit (buy-and-bill) rather than the pharmacy benefit, which changes the cost-sharing calculation significantly. Patients with a history of myocardial infarction or stroke within the prior year are not candidates due to a cardiovascular signal seen in the ARCH trial [11].

Denosumab (Prolia). A RANK-L inhibitor administered as 60 mg subcutaneously every 6 months, denosumab reduced vertebral fractures by 68% in the FREEDOM trial (N=7,868) [12]. It is not anabolic but carries a strong evidence base and is often on a preferred specialty tier on FCHP commercial plans.

How to Submit a Successful Prior Authorization to FCHP for Forteo

The prior authorization submission process for FCHP follows a standard pathway but benefits from specific documentation strategies that reduce back-and-forth.

Step 1: Gather objective bone data. Include the full DXA report with T-scores at lumbar spine, total hip, and femoral neck, the date of the scan, and the name of the interpreting facility. The National Osteoporosis Foundation recommends DXA every 1-2 years for patients on osteoporosis therapy, so recent scan data strengthens the case [13].

Step 2: Document fracture history. Spine X-ray reports confirming vertebral fractures, operative reports for hip or wrist fracture repair, or radiology reads confirming fragility fracture all strengthen the case. The Endocrine Society notes that a single low-trauma vertebral fracture is sufficient to diagnose osteoporosis regardless of T-score [7].

Step 3: Document bisphosphonate trial or exception basis. If the patient tried a bisphosphonate, include the dates of use, the dose, and the outcome (fracture on therapy, documented bone loss by DXA comparison, or adverse effect). If requesting a step-therapy exception, cite the Massachusetts statute and the AACE 2020 guideline recommendation for very-high-risk patients [6].

Step 4: Cite FRAX score. The FRAX tool, validated by the World Health Organization, estimates 10-year fracture probability and is accepted by most payers as supporting evidence for high-risk classification [14]. A 10-year major osteoporotic fracture probability above 20% or hip fracture probability above 3% meets the National Osteoporosis Foundation's intervention threshold [13].

Step 5: Use the correct FCHP prior authorization form. FCHP posts plan-specific forms on its provider portal. Using the correct form and checking all required fields prevents automatic administrative denials that delay care by 10-14 business days.

Step 6: Attach the AACE 2020 clinical practice guidelines. Physical attachment of relevant guideline pages to the PA submission creates a documented record that the prescriber's decision reflects published standards of care, which matters if the case proceeds to an external appeal [6].

What Happens If FCHP Denies Forteo Coverage?

A denial from FCHP does not end the process. Three sequential appeal options exist.

Internal appeal. FCHP must respond to a standard internal appeal within 30 days, or within 72 hours for an expedited (urgent) appeal. Submit the appeal with all updated clinical documentation, a letter of medical necessity, and any peer-reviewed literature supporting the indication. The NEJM teriparatide trial [2] and the AACE guidelines [6] are the strongest citations.

External independent medical review. If the internal appeal fails, Massachusetts law entitles FCHP members to an external review by an independent review organization (IRO) approved by the Massachusetts Division of Insurance. The IRO must issue a decision within 45 days for standard reviews or within 72 hours for urgent cases. IRO decisions are binding on FCHP [4].

Manufacturer patient assistance. Eli Lilly operates the Lilly Cares Foundation Patient Assistance Program, which provides Forteo at no cost to uninsured or underinsured patients who meet income eligibility criteria. Income thresholds and application details are available directly through Lilly's program [3]. The Forteo savings card for commercially insured patients can reduce out-of-pocket cost to as low as $25 per month for eligible patients who are not on Medicare or Medicaid [3].

Monitoring Requirements During Teriparatide Therapy

Coverage approval is not the end of the clinical story. FCHP and other payers typically require ongoing monitoring documentation for continuation authorizations.

Serum calcium should be checked 1-4 weeks after initiation because teriparatide transiently increases calcium levels, particularly in patients with pre-existing hypercalcemia [1]. The FDA prescribing information for Forteo lists hypercalcemia as a contraindication to initiating therapy [1].

DXA scanning at 12-18 months of therapy documents the anabolic response. Studies show lumbar spine BMD increases of 9-13% over 18 months with teriparatide, compared to 5-7% with bisphosphonates over a similar period [2]. FCHP continuation authorization requests typically require a follow-up DXA showing a positive or stable BMD response.

After completing the 24-month Forteo course, sequential anti-resorptive therapy is mandatory. Bone gains made during teriparatide therapy are lost within 12-18 months if no follow-on therapy is given, as shown by the San Francisco Coordinating Center follow-up analysis [15]. Zoledronic acid 5 mg as a single infusion following teriparatide completion further increased BMD by 6.6% at the lumbar spine compared to placebo in the DATA-Switch extension study (N=94) [15]. FCHP will often require a documented transition plan to anti-resorptive therapy as part of the second-year Forteo continuation authorization.

Cost-Sharing Estimates for FCHP Members Approved for Forteo

For FCHP commercial members with specialty tier cost-sharing, a 20-30% coinsurance on Forteo's list price of approximately $3,200 per month translates to $640-$960 per month before any copay maximums or manufacturer savings cards apply. Most FCHP commercial plans include an out-of-pocket maximum under the ACA's Section 1302 requirements, which for 2025 is $9,200 for an individual, meaning a patient who hits the OOP maximum early in the year pays nothing for subsequent Forteo fills that calendar year [5].

For FCHP Medicare Advantage members, the 2025 Part D $2,000 OOP cap represents a significant change. A patient filling Forteo monthly would reach the cap at approximately the third or fourth fill of the year and pay $0 thereafter for all Part D drugs [5].

MassHealth members pay a maximum of $3.65 per prescription fill, though formulary placement and prior authorization requirements still apply [4].

Patients should call the FCHP member services number on the back of their insurance card to request a formulary exception or a specific out-of-pocket estimate before initiating therapy. FCHP is required by Massachusetts law to provide a specific cost estimate upon member request.

Biosimilar Teriparatide: Does FCHP Prefer Bonsity?

TransEnterix's biosimilar teriparatide, Bonsity, received FDA approval in June 2021 and carries the same clinical data package as Forteo because biosimilar approval requires demonstration of no clinically meaningful differences from the reference product [1]. Bonsity's list price is approximately 20% lower than Forteo's, and FCHP formularies in some plan years have placed Bonsity at a preferred specialty tier while keeping Forteo at a non-preferred specialty tier.

Clinicians should check the current FCHP drug formulary at the time of prescribing. If Bonsity is preferred and the prescriber has no clinical reason to specify the brand-name product, writing "teriparatide" on the prescription (rather than "Forteo") may allow dispensing of whichever product is on formulary and reduce the member's cost-sharing.

The FDA notes that biosimilars approved through the 351(k) pathway, including Bonsity, are interchangeable with the reference product for the approved indications [1]. AACE guidelines do not differentiate between Forteo and Bonsity in their treatment recommendations [6].